Standardization and Antioxidant Activity of Propolis Extract for SARS-CoV2 Infection Therapy

Authors

  • Diah Kartika Pratami Faculty of Pharmacy, Pancasila University ,
  • Yesi Desmiaty Fakultas Farmasi, Universitas Pancasila ,
  • Evita Maria Simorangkir Fakultas Farmasi, Universitas Pancasila ,
  • Deby Faradhila Fakultas Farmasi, Universitas Pancasila ,

DOI:

https://doi.org/10.35814/jifi.v19i2.1062

Keywords:

Covid-19, encapsulation, powdered propolis microcapsules, supportive therapy

Abstract

Natural ingredients with immunomodulatory, anti-inflammatory, and antioxidant activities can be used as supportive therapy for SARS-CoV2 infection. The aims were standardized the quality and safety of propolis and determined the antioxidant activity of propolis. There are two types of propolis powder samples: microencapsulated propolis powder containing wax (SMPW) and non-waxed (SMP). Standardization includes specific and non-specific parameters. Antioxidant activity test using FRAP and ABTS methods. The total flavonoids of SMPW and SMP were 0.31% and 1.59%. The total phenolic of SMPW and SMP were 83.9082 and 98.0821 mg GAE/g. The losses on drying of SMPW and SMP were 3.65% and 3.88%. The water content of SMPW and SMP were 5.12% and 5.11%. The total ash content of SMPW and SMP were 0.80% and 0.65%. Heavy metal propolis powder negative. ALT and AKK values < 10 CFU/g, microbiology contamination was negative. Antioxidant activity of SMPW with IC50 ABTS 2.4177 ppm and EC50 FRAP 26.41 g/mL. Meanwhile, the antioxidant activity of SMP with IC50 ABTS 2.213 ppm and EC50 FRAP 32.10 g/mL. It was concluded that the extract of propolis met the requirements of the standard for extracts of natural ingredients and had strong antioxidant activity. Propolis powder can be developed for supportive therapy for SARS-CoV2 infection.

References

Downloads

Published

2021-10-31

Issue

Vol. 19 No. 2 (2021): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.